Soft tissue sarcoma

Issels RD, Prenninger SW, Nagele A, Boehm E, Sauer H, Jauch KW, Denecke H, Berger H, Peter K, Wilmanns W. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. Journal of Clinical Oncology (1990) Nov;8(11):1818-29. DOI: 10.1200/JCO.1990.8.11.1818

Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, Vujaskovic Z, Wessalowski R, Jauch KW, Dürr HR, Ploner F, Baur-Melnyk A, Mansmann U, Hiddemann W, Blay JY, Hohenberger P; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncology (2010) Jun;11(6):561-70. DOI: 10.1016/S1470-2045(10)70071-1.

Harnicek D, Kampmann E, Lauber K, Hennel R, Cardoso Martins AS, Guo Y, Belka C, Mörtl S, Gallmeier E, Kanaar R, Mansmann U, Hucl T, Lindner LH, Hiddemann W, Issels RD. Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair. International Journal of Cancer (2016) Jul 15;139(2):467-79. DOI: 10.1002/ijc.30070.

Issels R, Lindner LH. Regional hyperthermia for high-risk soft tissue sarcoma treatment: present status and next questions. Current Opinion Oncology (2016) Sep;28(5):447-52. DOI: 10.1097/CCO.0000000000000316.

Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, Ghadjar P, Hohenberger P, Angele M, Salat C, Vujaskovic Z, Daugaard S, Mella O, Mansmann U, Dürr HR, Knösel T, Abdel-Rahman S, Schmidt M, Hiddemann W, Jauch KW, Belka C, Gronchi A; European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. JAMA Oncology (2018) Apr 1;4(4):483-492. doi: 10.1001/jamaoncol.2017.4996.